Here’s hoping
that if the new patient data merit it, the company will opt for a more expressive press release headline than the usual, bland ‘Theralase releases XQ20YY newsletter’ fare. That formula works well enough for us, hardcore followers of the business, but is unlikely to attract many new readers and thus a missed opportunity PR/IR wise. It shouldn’t be too difficult to come up with something more eye-catching if the new data set is as good as the previous one.